This is the first commercially available test in Canada combining identification and therapeutic guidance information to support Resistance Guided Therapy for management of Mycoplasma genitalium (Mgen). Current Canadian management guidelines for Mgen direct laboratories to forward positive samples to the National Microbiology Laboratory for resistance testing. Now Canadian laboratories can utilize ResistancePlus MG and bring this service inhouse to generate more timely results for doctors and their patients.
“SpeeDx tests are designed to empower clinicians to make informed treatment decisions,” said Colin Denver, SpeeDx CEO. “Bringing ResistancePlus MG to Canada allows even more clinicians to access Resistance Guided Therapy, helping to improve patient cure rates and reduce overall health care costs.”
Read the full press release.